StockIQpro
NASDAQ:ORKA

Oruka Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Oruka Therapeutics, Inc. reported net income of −$105.4M in fiscal 2025. Free cash flow was −$88.4M.Summary generated from Oruka Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−41.4%
Debt / equityn/a
Free cash flow−$88.4M
FCF marginn/a
Share count changen/a

Financials

Fiscal years, $M
Item20202021202220232025
Revenue0000n/a
Operating income−10−19−11−7−122
Net income−10−19−10−5−105
Free cash flow−8−19−11−5−88

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations